TW201244717A - Treatment of attention deficit/hyperactivity disease - Google Patents

Treatment of attention deficit/hyperactivity disease Download PDF

Info

Publication number
TW201244717A
TW201244717A TW101109949A TW101109949A TW201244717A TW 201244717 A TW201244717 A TW 201244717A TW 101109949 A TW101109949 A TW 101109949A TW 101109949 A TW101109949 A TW 101109949A TW 201244717 A TW201244717 A TW 201244717A
Authority
TW
Taiwan
Prior art keywords
adhd
study
week
doc
test
Prior art date
Application number
TW101109949A
Other languages
English (en)
Chinese (zh)
Inventor
Merouane Bencherif
Geoffrey Charles Dunbar
David A Hosford
Gregory J Gatto
Terry Hauser
Kristen Jordan
Anthony Carl Segreti
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of TW201244717A publication Critical patent/TW201244717A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW101109949A 2011-03-23 2012-03-22 Treatment of attention deficit/hyperactivity disease TW201244717A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161466644P 2011-03-23 2011-03-23
US201161489740P 2011-05-25 2011-05-25
US201161510092P 2011-07-21 2011-07-21

Publications (1)

Publication Number Publication Date
TW201244717A true TW201244717A (en) 2012-11-16

Family

ID=45922840

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101109949A TW201244717A (en) 2011-03-23 2012-03-22 Treatment of attention deficit/hyperactivity disease

Country Status (3)

Country Link
AR (1) AR085483A1 (es)
TW (1) TW201244717A (es)
WO (1) WO2012129262A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103896826B (zh) * 2012-12-26 2016-08-03 上海朴颐化学科技有限公司 氮保护的(3r,4r)-3-甲氨基-4-甲基哌啶的不对称合成方法、相关中间体及原料制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه

Also Published As

Publication number Publication date
WO2012129262A1 (en) 2012-09-27
AR085483A1 (es) 2013-10-02

Similar Documents

Publication Publication Date Title
US11865126B2 (en) Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
ES2879631T3 (es) Pridopidina para el tratamiento de la enfermedad de Huntington
JP2022522659A (ja) 精神障害の処置における使用のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン（５－ｍｅｏ－ｄｍｔ）を含む組成物
Childress et al. Efficacy, safety, and tolerability of an extended-release orally disintegrating methylphenidate tablet in children 6–12 years of age with attention-deficit/hyperactivity disorder in the laboratory classroom setting
BR112019003732A2 (pt) Aplicação de pridopidina para tratamento de declínio funcional
AU2012207499A1 (en) Treatment of cognitive dysfunction in schizophrenia
JP2022548233A (ja) エスケタミンの鼻腔内投与
TW202102219A (zh) 使用氘化右旋美沙芬(dextromethorphan)及奎尼丁(quinidine)治療精神分裂症之負面徵候之方法
Steinbuchel et al. Stimulants: definition, pharmacology, indications, side effects, and treatment strategies
TW201244717A (en) Treatment of attention deficit/hyperactivity disease
Sarva et al. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia
JP2022524008A (ja) うつ病の治療のためのエスケタミン
TW201106944A (en) Exo-S-mecamylamine method, use, and compound for treatment
CA3237885A1 (en) Treatment of treatment resistant depression with psilocybin
Brown et al. Understanding and Managing New Onset Homicidal Ideation in an Adolescent with Depression
WO2023114097A1 (en) Psilocybin and an adjunctive serotonin reuptake inhibitor for use in the treatment of treatment-resistant depression
TW202400135A (zh) 包含阿替卡普蘭之組成物
Chew Anticholinergic medications and cognition in older adults
Kleinpeter et al. onian